KRAS and non-small cell lung carcinoma: As of February 2022, clinicaltrials.gov lists three clinical phase III trials (NCT05132075, NCT04685135, NCT04303780), evaluating KRAS G12C inhibitors in advanced and metastatic NSCLC harboring the specific KRAS G12C mutations that were previously treated with platinum-based chemotherapy and/or immune checkpoint inhibitor therapy.